Research led by the SKiN Center for Dermatology observed substantial clearance of scalp and body psoriasis and rapid itch ...

Icotrokinra demonstrated high rates of clearance in scalp and genital psoriasis after 16 weeks of treatment, according to ...

Using an existing steroid-free topical foam daily significantly improved the signs and symptoms of psoriasis on the scalp and ...

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study.

Roflumilast foam, 0.3% (Zoryve) used once-daily significantly improved itch and other symptoms of plaque psoriasis of the scalp and body, the phase III ARRECTOR trial showed.

Once-daily roflumilast foam significantly improves scalp and body psoriasis in 8 weeks and was well-tolerated in adolescents ...

Announcing a new publication for Acta Materia Medica journal. Psoriasis is a chronic inflammatory disorder for which phosphodiesterase-4 (PDE4) inhibitors have emerged as promising therapeutic agents ...

may improve treatment outcomes by increasing adherence. Roflumilast foam, 0.3% (Zoryve) used once-daily significantly improved itch and other symptoms of plaque psoriasis of the scalp and body ...

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis ... the potential for icotrokinra to shift the treatment paradigm in moderate-to-severe plaque ...

The FDA has issued an important alert regarding topical finasteride, highlighting significant health risks that many users remain unaware of until experiencing adverse effects. This warning comes ...